Literature DB >> 15982597

Outcome of hearts with cold ischemic time greater than 300 minutes. A case-matched study.

Fotios A Mitropoulos1, Jonah Odim, Daniel Marelli, Kalyani Karandikar, David Gjertson, Abbas Ardehali, Jon Kobashigawa, Hillel Laks.   

Abstract

OBJECTIVE: Expansion of potential donor pool may be facilitated by using cardiac allografts with long ischemic time. Early graft failure and potential relation to transplant coronary artery disease remains a concern. We sought to evaluate outcomes of heart transplantation in recipients of donor allografts with prolonged ischemia time.
METHODS: The study group consisted of 46 (mean age, 52 years) consecutive patients at UCLA from 1994 to 2002 that underwent heart transplantation with ischemia time > 300 min. This group was compared to a case-matched control group of 46 (mean age, 51 years) patients identified from our database during this time frame for the following factors: UNOS status, congenital heart disease diagnosis, preop inotropes, pretransplantation creatinine > 1.5 and recipient age. Primary endpoint was mortality and secondary were rejection rate and transplant coronary artery disease. Allografts were perfused and stored in cold University of Wisconsin solution.
RESULTS: Mean donor ages of the study and case-matched control group were 34+/-15 and 34+/-14 years, respectively. Mean ischemia times were 388 (range, 301-600 min) and 173 (range, 96-236 min), respectively. The death incidence rate per 100 transplants per year was 9% for the study group and 7.4% for the matched group (P = 0.50). Thirty-day mortality for the study and case-matched groups were 4.3 and 2.1%, respectively (P = 0.9). Late mortality was 16.5 and 18.5%, respectively (P = 0.9). The risk of death after 30 days was 7.5 and 5.8%, respectively (P = 0.5, log-rank). One-year incidence of acute cellular rejection in the study and case-matched groups were 2 and 4.5% (P = 0.36), respectively. One-year incidence of transplant coronary artery disease in the study and case-matched groups were 4.3 and 5.4%, respectively (P = 0.68).
CONCLUSIONS: Donor hearts with ischemia time greater than 300 min provide comparable early and intermediate outcomes given judicious and careful donor and recipient matching and our current techniques of myocardial preservation and modified reperfusion.

Entities:  

Mesh:

Year:  2005        PMID: 15982597     DOI: 10.1016/j.ejcts.2005.01.067

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation.

Authors:  Stjepan Barisin; Viktor Djuzel; Ana Barisin; Igor Rudez
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

2.  Association of graft ischemic time with survival after heart transplant among children in the United States.

Authors:  Mackenzie A Ford; Christopher S Almond; Kimberlee Gauvreau; Gary Piercey; Elizabeth D Blume; Leslie B Smoot; Francis Fynn-Thompson; Tajinder P Singh
Journal:  J Heart Lung Transplant       Date:  2011-06-14       Impact factor: 10.247

3.  Longer Ischemic Time is Associated with Increased Ventricular Stiffness as Measured by Pressure-Volume Loop Analysis in Pediatric Heart Transplant Recipients.

Authors:  Luke W Schroeder; Shahryar M Chowdhury; Ali L Burnette; Minoo N Kavarana; G Hamilton Baker; Andrew J Savage; Andrew M Atz; Ryan J Butts
Journal:  Pediatr Cardiol       Date:  2017-10-31       Impact factor: 1.655

Review 4.  Expanding Selection Criteria to Repairable Diseased Hearts to Meet the Demand of Shortage of Donors in Heart Transplantation.

Authors:  John H Yazji; Pankaj Garg; Ishaq Wadiwala; Mohammad Alomari; Emad Alamouti-Fard; Md Walid Akram Hussain; Samuel Jacob
Journal:  Cureus       Date:  2022-05-30

5.  Cardiac transplantation can be safely performed using selected diabetic donors.

Authors:  Sharven Taghavi; Senthil N Jayarajan; Lynn M Wilson; Eugene Komaroff; Jeffrey M Testani; Abeel A Mangi
Journal:  J Thorac Cardiovasc Surg       Date:  2013-03-13       Impact factor: 5.209

Review 6.  Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac Death.

Authors:  Stefano Toldo; Mohammed Quader; Fadi N Salloum; Eleonora Mezzaroma; Antonio Abbate
Journal:  Int J Mol Sci       Date:  2016-06-17       Impact factor: 5.923

Review 7.  Heart Donation and Preservation: Historical Perspectives, Current Technologies, and Future Directions.

Authors:  Nicholas R Hess; Luke A Ziegler; David J Kaczorowski
Journal:  J Clin Med       Date:  2022-09-28       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.